AdaptHealth (AHCO) Aktienübersicht
AdaptHealth Corp. vertreibt zusammen mit seinen Tochtergesellschaften in den Vereinigten Staaten häusliche medizinische Geräte (HME), medizinisches Zubehör sowie häusliche und damit verbundene Dienstleistungen. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 6/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für AHCO festgestellt.
AHCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AdaptHealth Corp. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$10.27 |
| 52-Wochen-Hoch | US$13.43 |
| 52-Wochen-Tief | US$8.51 |
| Beta | 1.45 |
| 1 Monat Veränderung | 3.84% |
| 3 Monate Veränderung | -13.99% |
| 1 Jahr Veränderung | 11.03% |
| 3 Jahre Veränderung | -18.43% |
| 5 Jahre Veränderung | -61.25% |
| Veränderung seit IPO | 6.98% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 22
AHCO: Tuck In Acquisitions And Refinancing Will Shape Future Earnings Profile
AdaptHealth’s latest Narrative Update reflects a modest adjustment to the analyst price target of around $11, as analysts incorporate slightly higher assumed revenue growth, profit margin, and discount rate, along with a marginally lower future P/E multiple in their models. Analyst Commentary on AdaptHealth Recent Street research on AdaptHealth points to a mixed but cautious tone.
Narrativ-Update • Jun 06
AHCO: Capitation Contract Execution Will Support Future Cash Flow Repricing
Narrative Update on AdaptHealth Analysts lifted the fair value estimate for AdaptHealth stock from $17 to $18, reflecting recent price target revisions across several firms that cite updated views on the company’s outlook and valuation assumptions. Analyst Commentary Recent Street research on AdaptHealth has centered on a series of price target resets, with several bullish analysts adjusting their models and one taking a more cautious stance.Narrativ-Update • May 22
AHCO: Capitated Contract Investments And Legal Settlement Will Shape Future Earnings Profile
Analysts have nudged their average price target on AdaptHealth higher to about $11.00 from $9.50, reflecting updated views on valuation inputs such as a higher assumed future P/E multiple and recent mixed target changes across firms raising and lowering their dollar-based estimates. Analyst Commentary Recent Street research on AdaptHealth reflects a mix of optimism and caution, with some firms lifting price targets and others trimming them as they reassess assumptions around earnings quality, execution and balance sheet risk.Recent updates
Narrativ-Update • Jun 22
AHCO: Tuck In Acquisitions And Refinancing Will Shape Future Earnings Profile
AdaptHealth’s latest Narrative Update reflects a modest adjustment to the analyst price target of around $11, as analysts incorporate slightly higher assumed revenue growth, profit margin, and discount rate, along with a marginally lower future P/E multiple in their models. Analyst Commentary on AdaptHealth Recent Street research on AdaptHealth points to a mixed but cautious tone.Narrativ-Update • Jun 06
AHCO: Capitation Contract Execution Will Support Future Cash Flow Repricing
Narrative Update on AdaptHealth Analysts lifted the fair value estimate for AdaptHealth stock from $17 to $18, reflecting recent price target revisions across several firms that cite updated views on the company’s outlook and valuation assumptions. Analyst Commentary Recent Street research on AdaptHealth has centered on a series of price target resets, with several bullish analysts adjusting their models and one taking a more cautious stance.Narrativ-Update • May 22
AHCO: Capitated Contract Investments And Legal Settlement Will Shape Future Earnings Profile
Analysts have nudged their average price target on AdaptHealth higher to about $11.00 from $9.50, reflecting updated views on valuation inputs such as a higher assumed future P/E multiple and recent mixed target changes across firms raising and lowering their dollar-based estimates. Analyst Commentary Recent Street research on AdaptHealth reflects a mix of optimism and caution, with some firms lifting price targets and others trimming them as they reassess assumptions around earnings quality, execution and balance sheet risk.Narrativ-Update • Apr 25
AHCO: Capitated Contract Ramp And Legal Settlement Will Pressure Future Earnings
Analysts have nudged their price targets for AdaptHealth higher by about $1 to $1.50, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions reflected in the latest model tweaks. Analyst Commentary Recent research updates show a mixed but generally cautious tone around AdaptHealth, even as some targets move higher at the margin.Narrativ-Update • Apr 10
AHCO: Capitation Contract Execution Will Drive Future Cash Flow Upside
Narrative Update on AdaptHealth Analysts have trimmed their price targets on AdaptHealth, with recent moves including cuts to $9.50 and $14. This reflects mixed views as they weigh operational progress, new capitation business, and recent EBITDA shortfalls and legal costs.Narrativ-Update • Mar 27
AHCO: Forward Contract Ramp And Legal Settlement Will Pressure Profitability
Analysts have trimmed AdaptHealth's consensus price target by $1 to $9.50, reflecting updated views on fair value, discount rates, and profitability after recent operational and legal developments. Analyst Commentary Bearish analysts have recently reset expectations on AdaptHealth, trimming price targets and calling out execution risks tied to both operations and legal events.Narrativ-Update • Mar 13
AHCO: Capitation Ramp And Cash Generation Will Drive Future Upside Potential
Analysts have trimmed their price targets on AdaptHealth, with recent cuts such as $10.50 to $9.50 and $15 to $14. These changes reflect updated views on the impact of increased upfront investment in a major capitated contract and a debt collection settlement on near term earnings.Narrativ-Update • Feb 27
AHCO: Capitation Ramp And Aging At Home Focus Will Support Upside
Narrative Update on AdaptHealth Analysts have trimmed their price targets on AdaptHealth, with recent cuts such as $10.50 to $9.50 and $15 to $14. These changes reflect updated views on the company after operational progress in 2025 was offset by the timing of investments to ramp a large capitated contract and a debt collection legal settlement in North Carolina that affected adjusted EBITDA versus guidance and estimates.Narrativ-Update • Feb 13
AHCO: Connected Health Initiative Will Support Aging At Home Upside
Analysts have kept their $17.00 price target for AdaptHealth unchanged, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margins, and future P/E as the main reasons for maintaining their view. What's in the News AdaptHealth is participating in a new Digital Medicine Society initiative focused on using connected health technology to support independent living for older adults at home.Narrativ-Update • Jan 30
AHCO: Digital Home Health Initiative Will Support Aging At Home Upside
Analysts are holding their fair value estimate for AdaptHealth at US$17.00 per share, citing only modest tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News AdaptHealth is participating in a Digital Medicine Society initiative focused on technology driven support for older adults living independently, working alongside partners including Validic, Epic Systems, Verizon and Withings to expand connected care and remote monitoring capabilities (Key Developments).Narrativ-Update • Jan 16
AHCO: Digital Home Health Initiative Will Support Aging At Home Opportunity
Analysts have lifted their price target on AdaptHealth from US$16.00 to US$17.00 as they factor in updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News AdaptHealth is participating in a Digital Medicine Society initiative focused on technology driven support for independent living among older adults, working alongside partners such as Validic, Epic Systems, Verizon, and Withings within the Connected Health Collaborative.Analyseartikel • Jan 03
AdaptHealth (NASDAQ:AHCO) Takes On Some Risk With Its Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Oct 18
Here's What's Concerning About AdaptHealth's (NASDAQ:AHCO) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to...Analyseartikel • Aug 08
AdaptHealth Corp. Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
NasdaqCM:AHCO 1 Year Share Price vs Fair Value Explore AdaptHealth's Fair Values from the Community and select yours...Analyseartikel • Jul 23
Insufficient Growth At AdaptHealth Corp. (NASDAQ:AHCO) Hampers Share Price
AdaptHealth Corp.'s ( NASDAQ:AHCO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right now...Analyseartikel • Jun 26
Is It Time To Consider Buying AdaptHealth Corp. (NASDAQ:AHCO)?
AdaptHealth Corp. ( NASDAQ:AHCO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively...Seeking Alpha • Jun 02
AdaptHealth At A Crossroads: Automation, Integration, And The Future Of Home Care
Summary AdaptHealth's national scale and AI-driven efficiencies position it well for value-based contracts, aiming to curb hospital readmissions and improve EBITDA margins. The company faces potential risks from competitive-bidding discounts, unresolved litigation, and execution challenges on the One Adapt ERP migration. Management's 2025 guidance suggests flat organic revenue and a 21% EBITDA margin, with shares appearing undervalued compared to peers. Long-term investors may find value in accumulating shares below 7× forward EBITDA, while monitoring integration milestones and CMS policy developments. Read the full article on Seeking Alpha
Neues Narrativ • May 15
Adapt Operating System And Debt Reduction Will Transform Home Healthcare
AdaptHealth's focus on geographic expansion, managed care, and partnerships aims to boost market share and drive revenue growth in the home health industry.Analyseartikel • May 14
We Think AdaptHealth's (NASDAQ:AHCO) Solid Earnings Are Understated
AdaptHealth Corp.'s ( NASDAQ:AHCO ) recent earnings report didn't offer any surprises, with the shares unchanged over...Analyseartikel • May 09
AdaptHealth Corp. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
AdaptHealth Corp. ( NASDAQ:AHCO ) last week reported its latest quarterly results, which makes it a good time for...Analyseartikel • Apr 07
Little Excitement Around AdaptHealth Corp.'s (NASDAQ:AHCO) Revenues
AdaptHealth Corp.'s ( NASDAQ:AHCO ) price-to-sales (or "P/S") ratio of 0.4x may look like a pretty appealing investment...Analyseartikel • Mar 20
At US$10.02, Is It Time To Put AdaptHealth Corp. (NASDAQ:AHCO) On Your Watch List?
AdaptHealth Corp. ( NASDAQ:AHCO ), might not be a large cap stock, but it saw a decent share price growth of 19% on the...Analyseartikel • Feb 26
These 4 Measures Indicate That AdaptHealth (NASDAQ:AHCO) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jan 30
Be Wary Of AdaptHealth (NASDAQ:AHCO) And Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analyseartikel • Dec 10
AdaptHealth Corp.'s (NASDAQ:AHCO) Revenues Are Not Doing Enough For Some Investors
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analyseartikel • Nov 13
We Think AdaptHealth (NASDAQ:AHCO) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Oct 22
Returns On Capital Signal Tricky Times Ahead For AdaptHealth (NASDAQ:AHCO)
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...Analyseartikel • Sep 06
AdaptHealth Corp.'s (NASDAQ:AHCO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
AdaptHealth Corp. ( NASDAQ:AHCO ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jul 14
Is There An Opportunity With AdaptHealth Corp.'s (NASDAQ:AHCO) 37% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, AdaptHealth fair value estimate is US$16.89 Current share...Analyseartikel • Jun 25
AdaptHealth Corp.'s (NASDAQ:AHCO) Low P/S No Reason For Excitement
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analyseartikel • Jun 04
AdaptHealth (NASDAQ:AHCO) Is Reinvesting At Lower Rates Of Return
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analyseartikel • Apr 03
Here's Why AdaptHealth (NASDAQ:AHCO) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Mar 07
Market Might Still Lack Some Conviction On AdaptHealth Corp. (NASDAQ:AHCO) Even After 50% Share Price Boost
AdaptHealth Corp. ( NASDAQ:AHCO ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Feb 16
AdaptHealth's (NASDAQ:AHCO) Returns On Capital Not Reflecting Well On The Business
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...Aktionärsrenditen
| AHCO | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 0.6% | 2.0% | 1.6% |
| 1Y | 11.0% | 28.7% | 18.6% |
Rendite im Vergleich zur Industrie: AHCO unter dem Niveau der Branche US Healthcare , die im vergangenen Jahr eine Rendite von 28.7% erzielte.
Rendite vs. Markt: AHCO hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| AHCO volatility | |
|---|---|
| AHCO Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: AHCO hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: AHCODie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2012 | 10,900 | Suzanne Foster | adapthealth.com |
AdaptHealth Corp. vertreibt zusammen mit seinen Tochtergesellschaften in den Vereinigten Staaten medizinische Geräte für den Hausgebrauch, medizinisches Zubehör sowie häusliche und damit verbundene Dienstleistungen. Das Unternehmen ist in den Segmenten Sleep Health, Respiratory Health, Diabetes Health und Wellness at Home tätig. Das Unternehmen bietet Schlaftherapiegeräte, Zubehör und damit verbundene Dienstleistungen an, wie z. B. kontinuierlichen positiven Atemwegsdruck und BiLevel-Dienste für Personen, die an obstruktiver Schlafapnoe leiden; Sauerstoff und Heimbeatmungsgeräte und -zubehör sowie damit verbundene chronische Therapiedienstleistungen; und medizinische Geräte, einschließlich kontinuierlicher Glukosemonitore und Insulinpumpen für die Behandlung von Diabetes; HME für Patienten, die aus der Akutversorgung und anderen Einrichtungen entlassen werden; und andere HME-Geräte und Zubehör.
AdaptHealth Corp.'s Grundlagenzusammenfassung
| AHCO grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.43b |
| Gewinn(TTM) | -US$79.63m |
| Umsatz(TTM) | US$3.29b |
0.4x
Kurs-Umsatz-Verhältnis-17.2x
Kurs-Gewinn-Verhältnis Ist AHCO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| AHCO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$3.29b |
| Kosten der Einnahmen | US$2.62b |
| Bruttogewinn | US$670.35m |
| Sonstige Ausgaben | US$749.98m |
| Gewinn | -US$79.63m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.60 |
| Bruttomarge | 20.40% |
| Nettogewinnspanne | -2.42% |
| Schulden/Eigenkapital-Verhältnis | 120.4% |
Wie hat sich AHCO auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/06 23:43 |
| Aktienkurs zum Tagesende | 2026/07/06 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AdaptHealth Corp. wird von 11 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Eric Coldwell | Baird |
| Kevin Fischbeck | BofA Global Research |
| Joanna Sylvia Gajuk | BofA Global Research |